162 related articles for article (PubMed ID: 15496319)
1. Identification of low-level degradants from low dose tablets.
Blanchard A; Lee C; Nickerson B; Lohr LL; Jensen AJ; Alsante KM; Sharp TR; Santafianos DP; Morris R; Snyder KD
J Pharm Biomed Anal; 2004 Oct; 36(2):265-75. PubMed ID: 15496319
[TBL] [Abstract][Full Text] [Related]
2. Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents.
Chen Q; Zielinski D; Chen J; Nowak S; Zhou CC
J Pharm Biomed Anal; 2009 Dec; 50(5):778-86. PubMed ID: 19581067
[TBL] [Abstract][Full Text] [Related]
3. Identification of volatile degradants in formulations containing sesame oil using SPME/GC/MS.
Chen W; Zhou P; Wong-Moon KC; Cauchon NS
J Pharm Biomed Anal; 2007 Jun; 44(2):450-5. PubMed ID: 17412547
[TBL] [Abstract][Full Text] [Related]
4. Isolation, identification and determination of the major degradation product in alprazolam tablets during their stability assay.
Huidobro AL; Rupérez FJ; Barbas C
J Pharm Biomed Anal; 2007 Jun; 44(2):404-13. PubMed ID: 17250986
[TBL] [Abstract][Full Text] [Related]
5. Identification, isolation and characterization of potential degradation product in risperidone tablets.
Bharathi Ch; Chary DK; Kumar MS; Shankar R; Handa VK; Dandala R; Naidu A
J Pharm Biomed Anal; 2008 Jan; 46(1):165-9. PubMed ID: 17981421
[TBL] [Abstract][Full Text] [Related]
6. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
Freed AL; Kale U; Ando H; Rossi DT; Kingsmill CA
J Pharm Biomed Anal; 2004 Jun; 35(4):727-38. PubMed ID: 15193717
[TBL] [Abstract][Full Text] [Related]
7. Forced degradation of fentanyl: identification and analysis of impurities and degradants.
Garg A; Solas DW; Takahashi LH; Cassella JV
J Pharm Biomed Anal; 2010 Nov; 53(3):325-34. PubMed ID: 20462721
[TBL] [Abstract][Full Text] [Related]
8. Identification of unknown impurities in simvastatin substance and tablets by liquid chromatography/tandem mass spectrometry.
Vuletić M; Cindrić M; Koruznjak JD
J Pharm Biomed Anal; 2005 Apr; 37(4):715-21. PubMed ID: 15797793
[TBL] [Abstract][Full Text] [Related]
9. Preparative isolation and high-resolution mass identification of 10 stressed study degradants of nicorandil tablets.
Prakash L; Malipeddi H; Subbaiah BV
J Chromatogr Sci; 2015 Jan; 53(1):122-6. PubMed ID: 24837014
[TBL] [Abstract][Full Text] [Related]
10. Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS.
Dongre VG; Karmuse PP; Ghugare PD; Gupta M; Nerurkar B; Shaha C; Kumar A
J Pharm Biomed Anal; 2007 Jan; 43(1):186-95. PubMed ID: 16916594
[TBL] [Abstract][Full Text] [Related]
11. Identification, isolation and characterization of a new degradation product in sultamicillin drug substance.
Kumar VJ; Gupta PB; Kumar KS; Ray UK; Sreenivasulu B; Kumar GS; Rao KR; Sharma HK; Mukkanti K
J Pharm Biomed Anal; 2011 Feb; 54(3):582-7. PubMed ID: 20934824
[TBL] [Abstract][Full Text] [Related]
12. The application of LC-NMR and LC-MS for the separation and rapid structure elucidation of an unknown impurity in 5-aminosalicylic acid.
Novak P; Tepes P; Fistrić I; Bratos I; Gabelica V
J Pharm Biomed Anal; 2006 Mar; 40(5):1268-72. PubMed ID: 16253464
[TBL] [Abstract][Full Text] [Related]
13. Rapid structure elucidation of drug degradation products using mechanism-based stress studies in conjunction with LC-MS(n) and NMR spectroscopy: identification of a photodegradation product of betamethasone dipropionate.
Lin M; Li M; Buevich AV; Osterman R; Rustum AM
J Pharm Biomed Anal; 2009 Oct; 50(3):275-80. PubMed ID: 19525081
[TBL] [Abstract][Full Text] [Related]
14. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR.
Dongre VG; Ghugare PD; Karmuse P; Singh D; Jadhav A; Kumar A
J Pharm Biomed Anal; 2009 May; 49(4):873-9. PubMed ID: 19201565
[TBL] [Abstract][Full Text] [Related]
16. Identification of degradation products in stressed tablets of Rabeprazole sodium by HPLC-hyphenated techniques.
Vasu Dev R; Sai Uday Kiran G; Venkata Subbaiah B; Suresh Babu B; Moses Babu J; Dubey PK; Vyas K
Magn Reson Chem; 2009 May; 47(5):443-8. PubMed ID: 19173350
[TBL] [Abstract][Full Text] [Related]
17. Comparison between liquid chromatography-UV detection and liquid chromatography-mass spectrometry for the characterization of impurities and/or degradants present in trimethoprim tablets.
Barbarin N; Henion JD; Wu Y
J Chromatogr A; 2002 Sep; 970(1-2):141-54. PubMed ID: 12350089
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of low level degradants in aztreonam injection and an innovative approach to aid HPLC method validation.
Ye Q; Ding W; Rinaldi F; Huang Y; Miller SA; Bolgar M
J Pharm Biomed Anal; 2016 May; 124():358-364. PubMed ID: 26991056
[TBL] [Abstract][Full Text] [Related]
19. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets.
Murakami T; Fukutsu N; Kondo J; Kawasaki T; Kusu F
J Chromatogr A; 2008 Feb; 1181(1-2):67-76. PubMed ID: 18191867
[TBL] [Abstract][Full Text] [Related]
20. Formation and identification of a degradant in chlorproguanil-dapsone-artesunate (Dacart™) tablets.
Bardsley B; Barry SJ; Drozdz MA; Hancock SA; Okafo GN; Szafran MM
J Pharm Biomed Anal; 2011 Feb; 54(3):610-3. PubMed ID: 20970278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
